COVID-19心血管疾病登记处: 开始, What Your Hospital Needs to Know
Thank you for your interest in the 美国心脏协会’s COVID-19心血管疾病登记处. The registry captures patient clinical characteristics, 药物, 治疗, 实验室, 重要器官, biomarkers and outcomes in adult (≥18 years old) patients hospitalized with COVID-19. A large focus lies on granular data collection from hospitals that routinely test biomarkers in COVID-19 patients.
While we welcome all hospitals to participate in the quality improvement (QI) program, hospitals with robust systems for running COVID-19 biomarkers on all adult hospitalized COVID-19 patients during the pandemic are highly encouraged to participate. The following information will help hospitals quickly register and access this no-cost opportunity.
登记
Please email the following information to (电子邮件保护) using the subject line, “[your hospital’s name] interest in COVID-19心血管疾病登记处 Participation”
- 医院名称和位置
- Which 遵循指南® (GWTG) modules hospital currently participates in, if any
- GWTG网站ID,如果参加
- Name and email of person leading the contracting
- Name and email of lead physician champion for the registry
- Do you have an onsite clinical chemistry laboratory? If yes, please describe its capacity for running serial standard blood tests.
Once received, AHA staff will review and contact you with any questions.
承包
Once your registration information is received, the 美国心脏协会 will review and contact you with any additional questions and appropriate contractual agreements.
Non-遵循指南 Hospitals:
Hospitals not already contracted for one of our GWTG programs will need to execute an online unified participation agreement (UPA).
遵循指南 Hospitals:
Hospitals already contracted for GWTG through the AHA UPA may:- sign a paper amendment to the UPA; or
- complete an online UPA solely for enrollment in COVID-19 CVD 质量改进 Registry.
- execute an online UPA to bring all of their modules under the UPA; or
- complete an online UPA solely for enrollment in COVID-19 CVD 质量改进 Registry.
注意: Similar to the 美国心脏协会’s existing suite of GWTG programs, the COVID-19 CVD registry is a QI program and data are collected and submitted as part of standard healthcare operations. Most hospitals participating in the other GWTG registries as well as this patient data registry do not require institutional review board (IRB) review. Your hospital IRB will determine whether participation is subject to or exempt from IRB oversight. 美国.S. 卫生署 & Human Services offers a resource of 质量改进 Activities 常见问题 that may help answer your specific IRB questions.